Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
Pediatr Infect Dis J
; 29(6): 563-6, 2010 Jun.
Article
en En
| MEDLINE
| ID: mdl-20160659
ABSTRACT
Fosamprenavir (FPV) efficacy in human immunodeficiency virus (HIV)-infected pediatric patients is still being evaluated in ongoing clinical trials. The long-term efficacy and safety of FPV boosted with ritonavir (FPV/r) was evaluated in 20 antiretroviral-naive and antiretroviral-experienced HIV-vertically infected pediatric patients. Analyses of CD4(+) T-cells, HIV-ribonucleic acid (RNA), and clinical status were performed during a median of 180 weeks. Initially, median HIV-RNA was 4.6 log(10) in naive and 4.4 log(10) in pretreated patients. Median CD4(+) T-cell was 17% and 31%, respectively. After FPV/r treatment, 18 of 20 patients achieved undetectable HIV-RNA and 4 of 20 experienced adverse events. To date, FPV/r treatment has shown sustained antiviral response and immunologic improvement in our 20 patients.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Organofosfatos
/
Sulfonamidas
/
Carbamatos
/
Infecciones por VIH
/
Fármacos Anti-VIH
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pediatr Infect Dis J
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
/
PEDIATRIA
Año:
2010
Tipo del documento:
Article
País de afiliación:
España